BridgeMD
New treatment option for Hip Osteoarthritis
Official title PENG Block With Dexmedetomidine in Older Adults
ClinicalTrials.gov ID: NCT07327372
What this study is testing
What is Ropivacaine 0.2% Injectable Solution?
Ropivacaine 0.2% Injectable Solution is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for hip osteoarthritis.
Also referred to as Ropivacaine hydrochloride.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Pain after hip surgery is a common problem in older adults and may delay early mobilization, increase the need for opioid pain medications, and contribute to complications such as delirium, nausea, or prolonged hospital stay. Regional anesthesia techniques are increasingly used to improve pain control while reducing the use of systemic opioids.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 65 to 100
You may be able to join if
- Age 65 years or older
- Scheduled for elective or emergency hip surgery (e.g., hip fracture fixation or hip arthroplasty)
- ASA physical status I-III
- Ability to communicate pain intensity using the NRS scale
- Written informed consent obtained from the patient or legal representative
You likely can't join if
- Patient refusal or inability to provide informed consent
- Allergy, intolerance, or contraindication to any study medication: ropivacaine, dexmedetomidine
- Pre-existing neurological deficit or neuropathy of the affected limb
- Coagulopathy (INR \>1.5, platelets \<100,000/µL) or current therapeutic anticoagulation that contraindicates regional anesthesia
- Infection at or near the injection site
- Severe hepatic or renal impairment
See the full eligibility criteria
- Age 65 years or older
- Scheduled for elective or emergency hip surgery (e.g., hip fracture fixation or hip arthroplasty)
- ASA physical status I-III
- Ability to communicate pain intensity using the NRS scale
- Written informed consent obtained from the patient or legal representative
- Planned use of PENG block as part of multimodal perioperative analgesia
- Patient refusal or inability to provide informed consent
- Allergy, intolerance, or contraindication to any study medication: ropivacaine, dexmedetomidine
- Pre-existing neurological deficit or neuropathy of the affected limb
- Coagulopathy (INR \>1.5, platelets \<100,000/µL) or current therapeutic anticoagulation that contraindicates regional anesthesia
- Infection at or near the injection site
- Severe hepatic or renal impairment
- History of chronic opioid use (daily opioids \>30 days before surgery)
- Cognitive impairment or delirium precluding reliable pain assessment
- BMI \> 40 kg/m² (if you want to exclude for technical difficulty)
- Patients receiving another regional nerve block for hip surgery
- Pregnancy or breastfeeding
- Participation in another treatment clinical trial within 30 days
The study team makes the final eligibility decision.
Where it's taking place
- Poznan, Poland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65 years to 100 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Poznan, Poland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.